Nichetti, F.; Ligorio, F.; Zattarin, E.; Signorelli, D.; Prelaj, A.; Proto, C.; Galli, G.; Marra, A.; Apollonio, G.; Porcu, L.;
et al. Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. Cancers 2020, 12, 67.
https://doi.org/10.3390/cancers12010067
AMA Style
Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A, Proto C, Galli G, Marra A, Apollonio G, Porcu L,
et al. Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. Cancers. 2020; 12(1):67.
https://doi.org/10.3390/cancers12010067
Chicago/Turabian Style
Nichetti, Federico, Francesca Ligorio, Emma Zattarin, Diego Signorelli, Arsela Prelaj, Claudia Proto, Giulia Galli, Antonio Marra, Giulia Apollonio, Luca Porcu,
and et al. 2020. "Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients" Cancers 12, no. 1: 67.
https://doi.org/10.3390/cancers12010067
APA Style
Nichetti, F., Ligorio, F., Zattarin, E., Signorelli, D., Prelaj, A., Proto, C., Galli, G., Marra, A., Apollonio, G., Porcu, L., de Braud, F., Lo Russo, G., Ferrara, R., & Garassino, M. C.
(2020). Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. Cancers, 12(1), 67.
https://doi.org/10.3390/cancers12010067
